10. A CLINICAL CASE OF AUDIO TOXICOLOGY RELATED TO MACROLID ANTIBIOTIC FROM NATIONAL LUNG HOSPITAL IN 2021
Main Article Content
Abstract
Audio ototoxicity refers to the damage with the inner structures of the ear (cochlea and vestibule) and their functions (hearing and balance) that can be experienced with exposure to certain drugs (eg, aminoside antibiotics, cisplatin, macrolides, etc.). Aminoside-associated ototoxicity is common to the doctor but hasn't been recognized and noticed with macrolide. We report a case of a patient presenting with tinnitus and hearing loss when using macrolide antibiotics for a long time in the treatment of NTM.
Article Details
Keywords
Macrolide, Azithromycin, auditory, NTM.
References
[1] Barbieri MA, Cicala G, Cutroneo PM et al.,
Ototoxic adverse drug reactions: A disproportionality
analysis using the Italian spontaneous reporting
database, Front Pharmacol, 2019.
[2] Ikeda AK, Prince AA, Chen JX et al., "Macrolide-
associated sensorineural hearing loss:
A systematic review", Laryngoscope. (2018)
128:228–36.
[3] Anna V, Berthe CO, Nelly FL et al., Macrolide-
associated ototoxicity: A cross-sectional
and longitudinal study to assess the association
of macrolide use with tinnitus and hearing loss,
Journal of Antimicrobial Chemotherapy. 76,
2021, pp. 2708–2716.
[4] Barbieri MA, Cicala G, Cutroneo PM et al.,
Ototoxic adverse drug reactions: A disproportionality
analysis using the Italian spontaneous
reporting database, Front Pharmacol. 10:1161.
10.3389/fphar.2019.01161, 2019.
[5] Brown BA, Griffith DE, Girard W et al., Relationship
of adverse events to serum drug levels
in patients receiving high-dose azithromycin
for mycobacterial lung disease, Clin Infect Dis,
1997, 24:958–64. 10.1093/clinids/24.5.958
[6] Griffith DE, Brown BA, Girard WM et al.,
Azithromycin activity against Mycobacterium avium
complex lung disease in patients who were
not infected with human immunodeficiency
virus", Clin Infect Dis(23:983–9. 10.1093/clinids/23.5.983), 1996.
[7] Guay DR, Patterson DR, Seipman N et al.,
Guay DR, Patterson DR, Seipman N, Craft JC.
Overview of the tolerability profile of clarithromycin
in preclinical and clinical trials.", Drug Saf. (1993)
8:350–64. 10.2165/00002018-199308050-00003.
[8] McGhan LJ, Merchant SN, Erythromycin
ototoxicity, Otol Neurotol, pp. 24:701–2.
10.1097/00129492-200307000-00029, 2003.
[9] Pawlowski KS, Si E, Wright CG et al., Ototoxicity
of topical azithromycin solutions in the
guinea pig, Arch Otolaryngol Head Neck Surg
136:481–7. 10.1001/archoto.2010.54, 2010.
[10] Tseng AL, Dolovich L, Salit IE, Azithromycin-
related ototoxicity in patients infected with
human immunodeficiency virus, N Engl J Med.
365:689–98.(10.1056/NEJMoa1104623), 2011.
Ototoxic adverse drug reactions: A disproportionality
analysis using the Italian spontaneous reporting
database, Front Pharmacol, 2019.
[2] Ikeda AK, Prince AA, Chen JX et al., "Macrolide-
associated sensorineural hearing loss:
A systematic review", Laryngoscope. (2018)
128:228–36.
[3] Anna V, Berthe CO, Nelly FL et al., Macrolide-
associated ototoxicity: A cross-sectional
and longitudinal study to assess the association
of macrolide use with tinnitus and hearing loss,
Journal of Antimicrobial Chemotherapy. 76,
2021, pp. 2708–2716.
[4] Barbieri MA, Cicala G, Cutroneo PM et al.,
Ototoxic adverse drug reactions: A disproportionality
analysis using the Italian spontaneous
reporting database, Front Pharmacol. 10:1161.
10.3389/fphar.2019.01161, 2019.
[5] Brown BA, Griffith DE, Girard W et al., Relationship
of adverse events to serum drug levels
in patients receiving high-dose azithromycin
for mycobacterial lung disease, Clin Infect Dis,
1997, 24:958–64. 10.1093/clinids/24.5.958
[6] Griffith DE, Brown BA, Girard WM et al.,
Azithromycin activity against Mycobacterium avium
complex lung disease in patients who were
not infected with human immunodeficiency
virus", Clin Infect Dis(23:983–9. 10.1093/clinids/23.5.983), 1996.
[7] Guay DR, Patterson DR, Seipman N et al.,
Guay DR, Patterson DR, Seipman N, Craft JC.
Overview of the tolerability profile of clarithromycin
in preclinical and clinical trials.", Drug Saf. (1993)
8:350–64. 10.2165/00002018-199308050-00003.
[8] McGhan LJ, Merchant SN, Erythromycin
ototoxicity, Otol Neurotol, pp. 24:701–2.
10.1097/00129492-200307000-00029, 2003.
[9] Pawlowski KS, Si E, Wright CG et al., Ototoxicity
of topical azithromycin solutions in the
guinea pig, Arch Otolaryngol Head Neck Surg
136:481–7. 10.1001/archoto.2010.54, 2010.
[10] Tseng AL, Dolovich L, Salit IE, Azithromycin-
related ototoxicity in patients infected with
human immunodeficiency virus, N Engl J Med.
365:689–98.(10.1056/NEJMoa1104623), 2011.